Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review outlines the complexities of understanding DHT biosynthesis and metabolism in the human prostate and reports no new findings, emphasizing the need for further research into the pathways involved.

This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.

This study found a strong dose-related increase in the risk of intracranial meningiomas associated with high doses of cyproterone acetate, with some reduction in risk after stopping the treatment.

Combining α-blockers and Finasteride is useful for treating small prostate enlargement.

This study found that intermediate hair follicles respond to testosterone by growing, but do not respond to finasteride, suggesting they may provide a novel and clinically relevant model for hair growth research.

In this study, men with persistent sexual dysfunction after stopping finasteride showed significant vascular, neurologic, and hormonal abnormalities, with severe erectile dysfunction being common.

This study describes a new method for assisting ureteral catheterization in challenging male patients, utilizing a Foley catheter mounted on a ureteroscope, which the authors found simple, effective, and promising where traditional methods fail.

This study found that polymers significantly improved the chemical and microbial stability of steroid hormones in liposome formulations over eight weeks, with finasteride showing the highest diffusion rate.

This study found that testosterone promotes proliferation, migration, and invasion in human glioblastoma cell lines through its conversion into dihydrotestosterone, which can be inhibited by drugs blocking 5α-reductase activity.

This review discusses managing prostate cancer in patients with high-risk germline mutations and highlights the need for more research and consensus guidelines, reporting no new clinical results.

This study found a significant association between male breast cancers and exposure to finasteride and dutasteride, with an estimated additional case per 564 men taking these drugs.

This study found that combining tamsulosin and finasteride significantly improved urinary symptoms and IPSS scores in elderly patients with benign prostatic hyperplasia compared to finasteride alone, with good safety profiles.

In this study, finasteride inhibited progesterone synthesis in mouse-derived MA-10 Leydig tumor cells by blocking cholesterol side-chain cleavage, but human and rat cells showed minimal sensitivity.

In this study, researchers found that finasteride inhibits progesterone synthesis by blocking cholesterol side-chain cleavage in mouse-derived MA-10 Leydig cells, but this effect may not be evident in human or rat cells.

This study found no association between androgenetic alopecia and increased prostate volume or serum PSA levels in male patients aged 25–45.

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.

This study found that patients with bladder outlet obstruction and moderately enlarged prostates are likely to successfully discontinue the a-blocker doxazosin after 9 months of combination therapy with finasteride.

This study found that finasteride does not increase the risk of high-grade prostate cancer but instead improves the prostate-specific antigen test's sensitivity to detect such cancers.

In this study, indications for monotherapy with 5-alpha-reductase inhibitors, such as finasteride and herbal drugs, were developed based on clinical and morphological changes in patients with benign prostatic hyperplasia.

This study found that finasteride significantly reduced prostate weight and DHT levels in male mastomys, but not in females, suggesting unique androgen metabolism in female prostates.

This study observed that equine epididymis mainly expresses the type 1 isoform of 5α-reductase and effectively converts progesterone and testosterone to DHP and DHT, while finasteride and dutasteride inhibited this activity.

SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.

This review discusses alternative androgen pathways, including the "backdoor" pathway and pathways to 11-oxygenated steroids, and reports no new clinical results; the authors aim to clarify these concepts for better patient treatment.

This review discusses the role of mental healthcare in managing sexual side effects of prostate cancer radiotherapy and highlights the importance of patient education and psychological support for improved quality of life.

This review found strong evidence supporting Finasteride's effectiveness in reducing symptoms and improving quality of life in patients with larger prostate volumes, earning it a grade A recommendation for clinical use.